aibioLatest Biogen news
We have not published a story on Biogen yet. When there is news, it will appear here.
What Biogen does
Biogen is a global biopharmaceutical company focused on neurology, specialized immunology and rare diseases. Its marketed multiple sclerosis medicines are VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY. Other marketed products include SPINRAZA for spinal muscular atrophy, SKYCLARYS for FA, and QALSODY for ALS. Biogen commercializes LEQEMBI for Alzheimer's disease with Eisai and ZURZUVAE for postpartum depression with Supernus. Through collaborations with Genentech, a member of the Roche Group, it holds rights to anti-CD20 therapies including RITUXAN, GAZYVA, OCREVUS and LUNSUMIO, and it commercializes the biosimilars BENEPALI, IMRALDI and FLIXABI. In November 2025 Biogen completed its acquisition of Alcyone Therapeutics, whose lead asset, ThecaFlex DRx, is an implantable port being investigated for intrathecal delivery of antisense oligonucleotides including SPINRAZA. Zorevunersen, an antisense oligonucleotide targeting SCN1A for Dravet syndrome that Stoke Therapeutics leads, has moved to a global Phase 3 trial. Biogen also has early-stage collaborations with Dayra Therapeutics, Vanqua Bio and City Therapeutics.
| Product or program | What it is | Stage |
|---|---|---|
| SPINRAZA | Treatment for spinal muscular atrophy | marketed |
| SKYCLARYS | Treatment for FA | marketed; the first and only drug approved for FA in the US, EU and certain other markets |
| QALSODY | Treatment for ALS | marketed |
| VUMERITY | Multiple sclerosis treatment | marketed |
| Zorevunersen | Antisense oligonucleotide targeting SCN1A for Dravet syndrome | global Phase 3 trial |
Biogen annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $9.89 billion | $9.68 billion |
| Net income (loss) | $1.29 billion | $1.63 billion |
| Cash from operations | $2.20 billion | $2.88 billion |
| Cash and equivalents | $3.01 billion | $2.38 billion |
| Short-term investments | $807.2 million | $0 |
Questions about Biogen
What is the ticker symbol of Biogen?
Biogen Inc. trades under the ticker BIIB on NASDAQ.
Where is Biogen listed?
Biogen Inc. is listed on NASDAQ. Our directory also records these other listings: BCBA:BIIB; BCBA:BIIB.CI; BCBA:BIIBD; BIVA:BIIB; BMFBOVESPA:BIIB34; BMV:BIIB; DUS:IDP; EUROTLX:4BIIB; FWB:IDP; GETTEX:IDP; HAM:IDP; HAN:IDP; LS:789617; LSE:0R1B; LSX:789617; MUN:IDP; SWB:IDP; TRADEGATE:IDP; VIE:BIIB; XETR:IDP.
What is the SEC CIK of Biogen?
The SEC Central Index Key (CIK) for Biogen Inc. is 875045. Its filings are on SEC EDGAR.
Which country or territory is Biogen listed under?
Our directory records Biogen Inc. under United States.
What does Biogen do?
Our directory classifies Biogen Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Biogen?
The ISIN recorded for Biogen Inc. is US09062X1037.
Does aibio.space cover Biogen?
aibio.space lists Biogen Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Biogen incorporated?
SEC records list its state or country of incorporation as DE.
What does Biogen develop?
Biogen is a global biopharmaceutical company focused on neurology, specialized immunology and rare diseases. Its marketed multiple sclerosis medicines are VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY.
What is SPINRAZA from Biogen?
SPINRAZA: Treatment for spinal muscular atrophy Stage: marketed.
What is SKYCLARYS from Biogen?
SKYCLARYS: Treatment for FA Stage: marketed; the first and only drug approved for FA in the US, EU and certain other markets.
What was Biogen's revenue last year?
$9.89 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Biogen profitable?
Biogen Inc. reported net income of $1.29 billion for the fiscal year ended Dec 31, 2025, and generated $2.20 billion of cash from operations, per its annual report to the SEC.
How much cash does Biogen have?
$1.30 billion in cash and short-term investments at Sep 30, 2026, per its 10-Q.
What is Biogen's market cap?
We do not publish live share prices. In its annual report, Biogen Inc. put the market value of shares held by non-affiliates (public float) at $18.38 billion as of Jun 30, 2025.
Investor discussion: Biogen
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Biogen Inc.
- CIK
- 875045
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- BIIB (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Phone
- 6176792000
- Former names
- BIOGEN IDEC INC.; BIOGEN IDEC INC; IDEC PHARMACEUTICALS CORP / DE
Recent filings
Listing details
- Company
- Biogen Inc.
- Ticker
- BIIB
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US09062X1037
- Other listed symbols
- BCBA:BIIB; BCBA:BIIB.CI; BCBA:BIIBD; BIVA:BIIB; BMFBOVESPA:BIIB34; BMV:BIIB; DUS:IDP; EUROTLX:4BIIB; FWB:IDP; GETTEX:IDP; HAM:IDP; HAN:IDP; LS:789617; LSE:0R1B; LSX:789617; MUN:IDP; SWB:IDP; TRADEGATE:IDP; VIE:BIIB; XETR:IDP
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction